Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer

OBJECTIVE To evaluate [11C]‐choline positron‐emission tomography (PET)/computed tomography (CT) for detecting clinical recurrence after primary treatment for prostate cancer. PATIENTS AND METHODS In all, 50 patients with prostate cancer who had had initial therapy (radical prostatectomy in 40, exter...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2007-10, Vol.100 (4), p.786-793
Main Authors: Rinnab, Ludwig, Mottaghy, Felix M., Blumstein, Norbert M., Reske, Sven N., Hautmann, Richard E., Hohl, Kathrin, Möller, Peter, Wiegel, Thomas, Kuefer, Rainer, Gschwend, Juergen E.
Format: Article
Language:English
Subjects:
11C‐choline PET
Aged
Biological and medical sciences
Choline
Follow-Up Studies
follow‐up
Gynecology. Andrology. Obstetrics
Humans
Male
Male genital diseases
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Staging
Nephrology. Urinary tract diseases
Prognosis
prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy - methods
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - therapy
PSA
Radiopharmaceuticals
re‐staging
Sensitivity and Specificity
Tomography, Emission-Computed - standards
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To evaluate [11C]‐choline positron‐emission tomography (PET)/computed tomography (CT) for detecting clinical recurrence after primary treatment for prostate cancer. PATIENTS AND METHODS In all, 50 patients with prostate cancer who had had initial therapy (radical prostatectomy in 40, external beam radiation in three and interstitial brachytherapy in seven) had PET/CT using [11C]‐choline in the presence of an increased or increasing prostate‐specific antigen (PSA) level. The mean (range) time to biochemical progression was 22 (2–136) months. Current PSA levels were determined in all patients at the time of examination. The results were correlated with the histopathology reports after targeted biopsy or surgery, and with the clinical follow‐up. RESULTS The mean (median, range) PSA level in patients with positive PET/CT was 3.62 (2.42, 0.5–13.1) ng/mL, and that in patients with a negative scan was 0.90 (0.95, 0.41–1.40) ng/mL. PET/CT was positive in seven of 13 patients with a PSA level of 5 ng/mL PET/CT identified all as positive and the histology was positive in eight. The sensitivity at a PSA level of
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2007.07083.x